EXHIBIT 99.1 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court da ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arbutus Biopharma (ABUS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Arbutus Biopharma is one of 1051 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different grou ...

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows: •Q1 2024 Press Release:Thursday, ...

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Conference: Form ...

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Conference: For ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Other ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Conference Call February 29, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, IR Michael McElhaugh - Interim President and CEO David Hastings - CFO and CAO Karen Sims - CMO Michael Sofia - CSO Conference Call Participants Dennis Ding - Jefferies Brian Skorney - Baird Roy Buchanan - Citizens JMP Thomas Yip - H.C. Wainwright Keay Nakae - Chardan Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Fourth Quarte ...

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Arbutus, which belongs to the Z ...

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows: •Q4 and Year ...

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody expected in 1H 2024 Preliminary data from a Phase 1a/1b clinical trial with AB-101, our oral PD-L1 inhibitor, expected in 1H 2024 Claim construction hearing for Moderna LNP litigation scheduled for February 8, 2024 Strong ...